AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.
Location: United States, Maryland, Baltimore
Employees: 11-50
Total raised: $10M
Founded date: 2008
Investors 2
Date | Name | Website |
- | Johns Hopk... | ventures.j... |
- | Sahsen Ven... | sahsen.com |
Funding Rounds 1
Date | Series | Amount | Investors |
13.09.2017 | - | $10M | - |
Mentions in press and media 13
Date | Title | Description | Source |
25.08.2023 | Rapport Therapeutics Snags $150M to Develop Precision Neurol... | Most available treatments for neurological disease act broadly across the brain, including in unwant... | medcitynew... |
13.09.2019 | AgeneBio receives $3.4M for development of Alzheimer’s treat... | Baltimore-based AgeneBio received over $3 million in new grant funding as the company looks to make ... | technical.... |
19.07.2019 | Role of seizures in Alzheimer’s disease is gaining overdue a... | Scientists who study Alzheimer’s disease have mostly ignored the role of seizures, but that is begin... | statnews.c... |
11.10.2018 | AgeneBio gets grants to advance therapeutics to slow Alzheim... | Baltimore-based AgeneBio announced a pair of grants from the National Institutes of Health that will... | technical.... |
13.09.2017 | AgeneBio to Receive up to $10 Million in NIH Funding | AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling... | citybizlis... |
17.09.2015 | This JHU startup is working on a treatment to prevent Alzhei... | A Johns Hopkins startup received a federal grant to enter trials of its treatment for a brain diseas... | technical.... |
18.03.2015 | Red Owl Analytics lands investment from Blackstone [Startup ... | WHO’S GETTING FUNDED Personal Genome Diagnostics won a contract from the U.S. Department of Veterans... | technical.... |
09.02.2015 | Citelighter teams up with Encyclopedia Britannica [Startup R... | WHO’S GETTING FUNDED Biotech continues to attract a lot of money to Baltimore. Over the last week, a... | technical.... |
24.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startup... | $4.1 million in equity raised of a proposed $10 million According to Phase IIa trials, its drug – le... | medcitynew... |
06.01.2012 | Alzheimer’s disease treatment uses anti-seizure meds to slow... | For its lead product, the company is repurposing an existing anti-seizure medication to prevent the ... | medcitynew... |
Show more